![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
The production, supply, research, and education of China's pharmaceutical industry, including modern medicine, medical devices, pharmaceutical machinery, packaging materials, and sanitary materials, have now formed a combination of industry and commerce, and production, management, scientific research, education, and design are complementary. The complete industry system has become an important part of the national economy and one of the fastest growing industries. In 1997, the market value of China's pharmaceutical industry was RMB 126.6 billion, of which RMB 73.2 billion was chemical products. According to statistics, there are currently more than 6,000 pharmaceutical industry enterprises in the country. Among them, there are 4 large-scale pharmaceutical enterprises, namely North China Pharmaceutical Co., Ltd., Northeast Pharmaceutical Group Corporation, Shandong Xinhua Pharmaceutical Group Co., Ltd. and Harbin Pharmaceutical Co., Ltd. There are about 300 large enterprises. Has become the world's second largest producer of bulk drugs. The output of antibiotics has reached 33,000 tons, and the output of vitamins has reached 29,000 tons, accounting for 30% of the world's production. The output of sulfonamides and antipyretic analgesics was 45,000 tons, which was among the highest in the world. At present, China has been able to produce about 1,300 kinds of raw materials and 3,500 kinds of standard products in 24 major categories of drugs, including antibiotics, sulfonamides, antipyretic analgesics, anticancer drugs, and cardiovascular drugs. The output of major preparations: powder injections can reach 9.65 billion, water needles can reach 55 billion, tablets 49.67 billion, capsules 30.8 billion, and infusions 1.37 billion bottles. With the improvement of the people’s living standards and economic development, the product structure and industrial structure of the pharmaceutical industry in China have also undergone significant changes. Specific performance in the following areas: 1. Drugs from the production of therapeutic drugs in the past mainly to the production of preventive drugs and health drugs direction transfer, from the past to the production of commonly used drugs to the development and production of special drug transfer, so production The production of chemical drugs continues to increase and new varieties continue to increase. For example, the proportion of penicillin and β-lactam drugs in the total amount of antibiotics has increased from 10% in 1990 to over 33% in 1997; the proportion of vitamin drugs in 24 categories of chemical raw material drugs increased from 8% in 1990 to In 1997, 14%; a large number of biotechnology drugs such as erythropoietin, colony-stimulating factor, 2B interferon, V-interferon, hepatitis B vaccine, insulin, etc. have been successfully developed, and began to put into industrial production. 2. Pharmaceutical products are more oriented to both domestic and international markets. Currently, there are more than 450 kinds of import and export drugs approved by China. The share of imported drugs and foreign-funded enterprises' products in the domestic market has reached more than 20%. 3. In order to improve the technological level of the pharmaceutical industry and actively use foreign technology and funds, since the reform and opening up, especially in the past five years, China has successively adhered to the principles of "new products, new technologies and export-oriented", and has The internationally renowned manufacturers such as the United States, Switzerland, Belgium, Germany, and Sweden have established more than 1,500 "three-funded" enterprises. Most of the world's top 20 pharmaceutical companies with the world's sales ranks have already established joint ventures or wholly-owned plants in China. In the field of medical devices, the United States GE, Hewlett-Packard and Germany's Siemens have also built factories in China. At present, there is still a big gap between China's pharmaceutical industry and advanced foreign companies, mainly in the following aspects: 1. Production is still in a low-level, small-scale stage. Many companies have similar products, lack of features, and more preparations. To highlight. Most varieties and enterprises have not formed a moderate scale economy, and their organizational structure is irrational. 2. There are few varieties. There are only 800 varieties that are actually produced each year and cannot be adapted to market needs. For example, there are only 20 kinds of slow controlled release agents, and the export variety structure is mainly low-grade raw material drugs.
Changzhou Jinxin ARTS & CRAFTS Co.,Ltd , https://www.jxpartyconfetti.com